Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mink Therapeutics Inc
(NQ:
INKT
)
1.100
-0.160 (-12.70%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mink Therapeutics Inc
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
September 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
August 24, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
August 10, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
July 28, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
May 22, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
May 18, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
May 11, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
April 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
April 18, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
March 30, 2023
From
Agenus Inc.
Via
Business Wire
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 21, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
March 15, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
March 07, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
February 16, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
January 11, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
November 17, 2022
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
November 10, 2022
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
November 03, 2022
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
October 20, 2022
Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Host R&D Event November 10, 2022
October 05, 2022
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
July 27, 2022
Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET
From
MiNK Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.